References

REFERENCES


[1] La Vecchiam, C., Negri, E., Franceschi, S., Parazzini, F. (1993). Long-term impact of reproductive factors on cancer risk. Int J Cancer, Jan 21, 53(2), 215-9.

[2] Medard, M.L., Ostrowska, L. (2007).Combined oral contraception and the risk of reproductive organs cancer in women .Ginekol Pol, Aug,78(8), 637-41.

[3] Casey, P.M., Cerhan, J.R., Pruthi, S. (2008). Oral contraceptive use and risk of breast cancer. Mayo Clin Proc,Jan,83),86-90

[4] Deligeoroglou, E., Michailidis, E., Creatsas, G. (2003).Oral contraceptives and reproductive system cancer. Ann N Y Acad Sci,Nov,997,199-208.

[5] White, E., Malone, K.E., Weiss, N.S., Daling, J.R. (1994). Breast cancer among young US women in relation to oral contraceptive use. J. Nati Cancer Inst, 86(7), 505-14

[6] Brohet, R.M., Goldgar, D.E., Easton, D.F., Antoniou, A.C., Andrieu, N., Chang-Claude, J., Peock, S., Eeles, R.A., Cook, M., Chu, C., Noguès, C., Lasset, C., Berthet, P., Meijers-Heijboer, H., Gerdes, A.M., Olsson, H., Caldes, T., van Leeuwen, F.E., Rookus, M.A. (2007). Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.J Clin Oncol, Sep 1,25(25), 3831-6.

[7] Haile, R.W., Thoma, D.C., McGuire, V., Felberg, A., John, E.M., Milne, R.L., Hopper, J.L. et.al. (2006). BRCA1 and BRCA2 mutation carriers, oral contraceptives use,and breast cancer before age 50. Cancer Epidemiol.Biomarker Prev, 15(10), 1863-70.

[8] Daling, J.R., Brinton, L.A., Voigt, L.F., Weiss, N.S., Coates, R.J., Malone, K.E., Schoenberg, J.B., Gammon, M. (1996). Risk of breast cancer among white women following induced abortion. Am J Epidemiol, Aug 15,144(4), 373-80.

[9] Daling, J.R., Malone, K.E., Voigt, L.F., White, E., Weiss, N.S. (1997). Risk of breast cancer among young women: relationship Med to induced abortion. N Engl J, 336(2), 81-5

[10] Rookus, M.A., van Leeuwen, F.E. (1996).Induced abortion and risk for breast cancer: reporting (recall) bias in a Dutch case-control study. J Natl Cancer Inst, 88 (23),1759-64

[11] Van Leeuwen, F.E. (1991). Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer. Acta Endocrinol, 125(1), 13.

[12] Kodama, M., Kodama, T., Seeger, H., Rakov, V., Mueck, A.O. (1981).Adolescence, a critical stage for the genesis of female cancers (review) Anticancer Res,1(2), 93-9.

[13] La Vecchia, C., Tavani, A., Franceschi, S., Parazzini, F. (1996). Oral contraceptives and cancer.A review of the evidence.Drug Saf, 14(4), 260-72.

[14] Seeger, H., Rakov, V., Mueck, A.O. (2005). Dose-dependent changes of the ratio of apoptosis to proliferation by norethisterone and medroxyprogesterone acetate in human breast epithelial cells. Horm Metab Res,Aug, 37(8), 468-73.

[15] Sweeney, C., Giuliano, A.R., Baumgartner, K.B., Byers, T., Herrick, J.S., Edwards, S.L., Slattery, M.L. (2007). Oral, injected and implanted contraceptives and breat cancer risk among US Hispanic and non-Hispanic white women. Int. J. Cancer,121 (11), 2517-23.

[16] Altaha, R., Reed, E., Abraham, J.Breast and ovarian cancer genetics and prevention.) Burke, W., Daly, M., Garber, J., Botkin, M.J., Lynch, P., McTiernan, A., Offit, K. (2003). WV Med J,99(5),187-91.

[17] Fraser, I.S., Kovacs, G.T. (2003). The efficacy of non-contraceptive uses for hormonal contraceptives. Med J Aust, Jun 16,178(12),621-3.

[18] Kehoe, S.M., Kauff, N.D. (2007).Screening and prevention of hereditary gynecologic cancers. Semin Oncol,Oct, 34(5), 406-10.

[19] Burke, W., Daly, M., Garber, J., Botkin, M.J., Lynch, P., McTiernan, A., Offit, K., Periman, J., Petersen, G., Thomson, E.,Varricchio,C. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II BRCA1 and BRCA2. Cancer Genetics Studies Consortiun. JAMA,26, 277(12),997-1003. Review.

[20] Verheijen, R.H., Boonstra, H., Menko, F.H., de Graaff, J., Vasen, H.F., Kenter, G.G. (2002). Recommendations for the management of women with an increased genetic risk of gynaecological cancer. Ned Tijdschr Geneeskd, Dec 14,146(50), 2414-8.

[21] Casey, M.J., Synder, C., Bewtra, C., Narod, S.A., Watson, P., Lynch, H.T. (2005). Intra- abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome associated with BRCA1 and BRCA2 mutations. Gynecol Oncol,May, 97(2), 457-67.

[22] Merki-Feld, G.S., Seeger, H., Mueck, A.O. (2008). Comparison of the proliferative effects of ethinylestradiol on human breast cancer cells in an intermittent and a continuous dosing regime. Horm Metab Res, Mar, 40(3), 206-9.

[23] Kramer, E.A., Seeger, H., Kramer, B., Wallwiener, D., Mueck, A.O. (2006). The effect of progesterone, testosterone and synthetic progestogens on growth factor- and estradiol-treated human cancerous and benign breast cells. Eur J Obstet Gynecol Reprod Biol, Nov,129(1), 77-83.

[24] Hanna, L., Adams, M. (2006).Prevention of ovarian cancer.Best Pract. Res. Obstet.Gynaecol, 20(2), 339-627.

[25] Persson, I. (2000). Estrogens in the causation of breast, endometrial and ovarian cancers - evidence and hypotheses from epidemiological findings. J Steroid Biochem Mol Biol, 74(5), 357-64.

[26] Riman, T., Nilsson, S., Persson, I.R. (2004). Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet. Gynecol. Scand, 83(9),783-95

[27] Greer, J.B., Modugno, F., Allen, G.O., Auranen, A., Hietanen, S., Salmi, T.,Grénman, S. (2005). Hormonal treatments and epithelial ovarian cancer risk. Int. J. Gynaecol Cancer,15(5), 692-700.

[28] Burkman RT. (2002).Reproductive hormones and cancer: ovarian and colon cancer. Obstet Gynecol Clin North Am, Sep,29(3), 527-40.

[29] Beral, V., Doll, R., Hermon, C., Peto, R., Reeves, G. (2008). Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives:collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet, Jan 26, 371(9609), 303-14.

[30] Ness, R.B. (2005). Androgenic progestins in oral contraceptives and the risk of epithelial ovarian cancer. Obstet. Gynecol, 105(4), 731-40.

[31] Sanderson, M.,Williams, M.A.,Weiss, N.S., Hendrix, N,W., Chauhan, S.P. (2006). Oral contraceptives and epithelial ovarian cancer.Does dose matter? J.Reprod.Med,45(9), 720-6.

[32] Lurie, G., Thompson, P., McDuffie, K.E., Carney, M.E., Terada, K.Y.,Goodman, M.T. (2007). Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk. Obstet.Gynecol,109(3), 597-607.

[33] Schildkraut, J.M.,Calingaert, B.,Manchbanks, P.A., Moorman, P.G., Rodriguez, G.C. (2002). Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J.Natl.Cancer, 94(1), 32-8.

[34] Lancaster, J.M., Powell, C.B., Kauff, N.D., Cass, I., Chen, L.M., Lu, K.H., Mutch, D.G.,Berchuck, A., Karlan, B.Y., Herzog, T.J. (2007). Society of Gynecologic Oncologists Education Committee.Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol,107 (2), 159-62.

[35] Pujol P, This P, Noruzinia M, Stoppa - Lyonnet D, Maudelonde T. (2004). Are the hereditary forms of BRCA 1 and BRCA 2 breast cancer sensitive to estrogens? Bull.Cancer, 91(7-8),583 91.

[36] Auranen, A., Hietanen, S., Salmi, T., Grénman, S. Hormonal treatments and epithelial ovarian cancer risk. Int J Gynecol Cancer, 15(5), 692-700. 35)

[37] The ESHRE Capri Workshop Group. Noncontraceptive health benefits of combined oral contraception. (2005). Hum. Reprod. Update, 11(5), 513-25

[38] Pike, M.C., Spicer, D.V. (2000). Hormonal contraception and chemoprevention of female cancers. Endocr Relat Cancer, Jun, 7(2), 73-83.

[39] Henderson, B.E., Ross, R.K., Pike, M.C. (1993). Hormonal chemoprevention of cancer in women. Science, 259(5095),633-8.

[40] Maxwell, G.L., Schildkraut, J.M., Calingaert, B., Risinger, J.I., Dainty, L., Marchbanks, P.A., Berchuck, A., Barrett, J.C., Rodriguez, G.C. (2006). Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol, Nov,103(2), 535-40.

[41] Voight, L.F., Deng, Q.,Wwiss, N.S. (1994). Recency,duration,and progestin content of oral contraceptives in relation to the incidence of endometrial cancer. Cancer Causes.Control,5(3), 227-33.

[42] Bernstein, L. (2006). The risk of breast, endometrial and ovarian cancer in users of hormonal preparations. Basic Clin Pharmacol Toxicol, Mar, 98(3), 288-96

[43] Horn, L.C., Schnurrbusch, U., Bilek, K., Hentschel, B., Einenkel, J. (2004). Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer,14(2),348-53.

[44] Medl, M. (1998).Oral contraceptives and endometrial and ovarian carcinomas.Gynakol Geburtshilfliche Rundsch, 38(2), 105-8.

[45] Kresowik, J., Ryan, G.L., Van Voorhis, B.J. (2008). Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system. Obstet Gynecol,111(2 ), 547- 9.

[46] Rizkalla, H.F., Higgins, M., Kelehan, P., O'Herlihy, C. (2008). Pathological findings associated with the presence of a mirena intrauterine system at hysterectomy.Int J Gynecol Pathol, Jan, 27(1),74-8.

[47] Prilepskala, V.N., Kondrikov, N.I., Nazarova, N.M. (1991). Morphofunctional features of the cervix uteri in women using hormonal contraception Akush.Ginekol.(Mosk),12, 6-10.

[48] International Collaboration of Epidemiological Studies of Cervical Cancer. Appleby, P., Beral, V., Berrington de Gonzalez, A., Colin, D., Franceschi, S., Goodhill, A., Green, J., Peto, J., Plummer, M., Sweetland, S. (2007). Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies.Lancet, 370(9599), 1609-21.

[49] Shapiro, S., Rosenberg, L., Hoffman, M., Kelly, J.P., Cooper, D.D., Carrara, H., Denny, L.E., du Toit, G., Allan, B.R., Stander, I.A., Williamson, A.L. (2003). Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives. Cancer Causes Control, 14(5), 485-95.

[50] Syrjanen, K., Shabalova, I., Petrovichev, N., Kozachenko, V., Zakharova,T., Pajanidi, J., Podistov, J., Chemeris, G., Sozaeva, L., Lipova, E., Tsidaeva, I. (2006). Oral contraceptives are not an independent risk factor for cervical intraepithelial neoplasia or high-risk human papillomavirus infections. Anticancer Res,26(6C),4729-40. [51] De Villiers, E.M. (2003). Relationship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma.Int.J.Cancer, 103(6), 70

[52] Moodley, M., Moodley, J.,Chetty, R., Herrington, C.S. (2003). The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer:a review. Int.J.Gynecol.Cancer, 13(2), 103-10

[53] Green, J., Berrington deGonzales, A., Smith, J.S.M., Franceschi, S., Appleby, P., Plummer, M., Beral, V. (2003). Human papillomavirus and use of oral contraceptives.Br.J.Cancer,88(11),1713-20.

[54] Smith, J.S., Green, J., Berrington de Gonzalez, A., Appleby, P., Peto, J., Plummer, M., Franceschi,S., Beral, V. (2003). Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet, Apr 5, 361(9364), 1159-67.

[55] Le, M.G., Bachelot, A., Doyen, F., Kramar, A. (1985). A study on the association between the use of oral contraception and cancer of the breast or cervix:preliminary findings of a French study. Contracept. Fertil. Sex(Paris), 13(3), 553-8.

[56] Vanakankovit N., Taneepanichskul S. (2008). Effect of oral contraceptives on risk of cervical cancer. J.Med.Assoc. Thai, 91(1), 7-12.

[57] Moreno, V., Bosch, F.X., Munoz, N., Meijer, C.J., Shah, K.V.,Walboomers, J.M., Herrero, R., Franceschi, S. (2002). International Agency for Research on Cancer, Multicentric Cervical Cancer Study Group. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection:the IARC multicentric case-control study. Lancet, 359 (9312), 1085-92.

[58] Sasieni, P. (2007). Cervical cancer prevention and hormonal contraception. Lancet,370 (9599),1591-2.

[59] Scharz E.B., Sain, M., Gildengorin, G., Weitz T.A., Stewart, F.H., Sawaya G.F.(2005). Cervical cancer screening continues to limit provision of contraception. Contraception, 72(3), 179-81.

[60] Bertram, C.C. (2004). Evidence for practice:oral contraception and risk of cervical cancer. J. Am. Acad.Nurse Pract, 16(10),455-61.

[61] Misra, J.S., Tandon, P.,Srivastava, A.,Das, K., Chandrawati Saxena, N.C. (2003). Cervical cytological studies in women inserted with Norplant-contraceptive.Diagn.Cytopathol,29(3), 136-9.

[62] Moscicki, A.B., Ellenberg, J.H.,Vermund, S.H., Holland, C.A., Darragh, T., Crowley-Nowick, P.A., Levin, L.,Wilson, C.M. (2000). Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls:impact of infection with human immunodeficiency virus.Arch.Pediatr.Adolesc.Med, 154(2), 127-34.

[63] Moscicki, A.B., Ellenberg, J.H., Crowley-Nowick, P., Darragh, T.M., Xu, J., Fahrat, S, (2004). Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents.J.Infect.Dis, 190(8),1413-21

[64] Fernandez, E., La Vecchia, C., Franceschi, S., Braga, C., Talamini, R., Negri, E., Parazzini, F. (1998). Oral contraceptive use and risk of colorectal cancer. Epidemiology,9(3), 295-300.

[65] Talamini, R., Franceschi, S., Dal Maso, L., Negri, E., Conti, E., Filiberti, R., Montella, M., Nanni, O., La Vecchia, C. (1998). The influence of reproductive and hormonal factors on the risk of colon and rectal cancer in women. Eur J Cancer, 34(7), 1070-6.

[66] Chute, C.G., Willett, W.C., Colditz, G.A., Stampfer, M.J., Rosner, B., Speizer, F.E. (1991). A prospectivestudy of reproductive history and exogenous estrogens on the risk of colorectal cancer in women. Epidemiology, May, 2(3), 201-7.

[67] Jacobson, J.S., Neugut, A.I., Garbowski, G.C., Ahsan, H., Waye, J.D., Treat, M.R., Forde, K.A. (1995). Reproductive risk factors for colorectal adenomatous polyps (New York City, NY, United States). Cancer Causes Control, Nov, 6(6), 513-8.

[68] Potter, J.D., Bigler, J., Fosdick, L., Bostick, R.M., Kampman, E., Chen, C., Louis, T.A., Grambsch, P. (1999). Colorectal adenomatous and hyperplastic polyps: smoking and N-acetyltransferase 2 polymorphisms. Cancer Epidemiol Biomarkers Prev, 8(1), 69-75.

[69] Jacobs, E.J., White, E., Weiss, N.S. (1994). Exogenous hormones, reproductive history, and colon cancer (Seattle, Washington, USA). Cancer Causes Control,Jul, 5(4), 359-66

[70] Kabat, G.C., Miller, A.B., Rohan, T.E. (2008).Oral contraceptive use, hormone replacement therapy, reproductive history and risk of colorectal cancer in women. Int J Cancer, 1,122(3), 643-6.

[71] Lin, J., Zhang, S.M., Cook, N.R., Manson, J.E., Buring, J.E., Lee, I.M.(2007). Oral contraceptives, reproductive factors, and risk of colorectal cancer among women in a prospective cohort study. Am J Epidemiol, 165(7), 794-801.

[72] Slattery, M.L., Ballard-Barbash, R., Potter, J.D., Ma, K.N., Caan, B.J., Anderson, K., Samowitz, W. (2004). Sex-specific differences in colon cancer associated with p53 mutations.Nutr Cancer,49(1), 41-8.

[73] Slattery, M.L., Ballard-Barbash, R., Edwards, S., Caan, B.J., Potter, J.D. (2003). Body mass index and colon cancer: an evaluation of the modifying effects of estrogen (United States).Cancer Causes Control, 14(1), 75-84.

[74] Giardiello, F.M., Hylind, L.M., Trimbath, J.D., Hamilton, S.R., Romans, K.E., Cruz-Correa, M., Corretti, M.C., Offerhaus, G.J., Yang, V.W. (2005). Oral contraceptives and polyp regression in familial adenomatous polyposis. Gastroenterology, Apr,128(4), 1077-80.

[75] Hannaford, P., Elliott, A.1. (2005). Use of exogenous hormones by women and colorectal cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study. Contraception,71(2), 95-8.

[76] Leslie, K.K., Espey, E. (2005). Oral contraceptives and skin cancer:is there a link? Am.J.Clin. Dermatol, 6(6), 349-55.

[77] Pierard, G.E.,Pierard - Franchimont, C.,Quatresooz, P., Kridelka, F.,Gaspard, U. (2007).Groupe Mosan d'Etudes Tumeurs Pigmentaires. Can we sort out from the jumble about oral contraceptives and skin cancer? Rev.Med.Liege, 62(5-6),463-6.

[78] Gefeller, O., Hassan, K.,Wille, L. (1988). Cutaneous malignant melanoma in women and the role of oral contraceptives. Br.J.Dermatol, 138(1), 122-4.

[79] Lea, C.S., Holly, E.A., Hartge, P., Lee, J.S., Guerry, D. (2007). 4th ,Elder DE, Halpern A, Sagebiel RW, Tucker MA. Reproductive risk factors for cutaneous melanoma in women:a case- control study. Am.J.Epidemiol, 165(5), 505-13.

[80] Smith, M.A., Fine, J.A., Barnhill, R.L., Berwick, M. (1998). Hormonal and reproductive influences and risk of melanoma in women. Int.j. Epidemiol, 27(5), 751-7.

[81] Holly, E.A.,Cress, R.D., Ahn, D.K. (1995).Cutaneous melanoma in women. III. Reproductive factors and oral contraceptive use. Am.J.Epidemiol, 141(10), 943-50.

[82] Naldi, L., Altieri, A., Imberti, G.E., Giordano, L., Gallus, S., LaVecchia, C. (2005). Oncology Study Group of the Italian Group for Epidemiologic Research in Dermatology(GISED). Cutaneous malignant melanoma in women. Phenotypic characteristics, sun exposure, and hormonal factors: a case control study from Italy. Ann. Epidemiol,15(7), 545-50.

[83] Osterlind, A. (1992). Hormonal and reproductive factors in melanoma risk.Clin.Dermatol,10(1), 75-8.

[84] Zanetti, R., Franceschi, S., Rosso, S., Bidoli, E.,Colonna, S. (1990). Cutaneous malignant melanoma in females: the role of hormonal and reproductive factors.Int.J. Epidemiol,19(3),522-6.

[85] Breitbart, M.,Garbe, C., Buttner P,Weiss, J., Soyer, H.P., Stocker, U., Kruger, S., Breitbart, E.W., Weckbecker, J., Panizzon, R., Bahmer, F., Tilgen, W., Guggenmoos-Holzmann, I., Orfanos, C.E. (1997). Ultraviolet light exposure, pigmentary traits and the development of melanocytic naevi and cutaneous melanoma.A case-control study of the German Central Malignant Melanoma Registry. Acta Derm.Venereol, 77(5), 374-8.

[86] Beral, V., Evans, S., Shaw, H., Milton, G. (1984). Oral contraceptive use and malignant melanoma in Australia. Br.J.Cancer, 50(5), 681-5.

[87] Karagas, M.R., Zens, M.S., Stukel, T.A., Swerdiow, A.J., Rosso, S., Osterlind, A., Mack, T., Kirkpatrick, C., Holly, E.A., Green, A., Gallagher, R., Elwood, J.M., Armstrong, B.K. (2006). Pregnancy history and incidence of melanoma in women:a pooled analysis. Cancer Causes Control,17(1), 11-9.

[88] Green, A. (1991). Oral contraceptives and skin neoplasia. Contraception, 43(6), 653-66.

[89] Rosso, S., Zanetti, R., Pippione, M., Sancho-Garnier, H. (1998). Parallel risk assessment of melanoma and basal cell carcinoma: skin characteristics and sun exposure. Melanoma Res, 8(6), 573-83.

[90] Bosetti C,La Vecchia C,Naldi L,Lucchini F,Negri E,Levi F. (2004). Mortality from cutaneous malignant melanoma in Europe. Has the epidemic level off? Melanoma Res,14(4), 301-9.

[91] Nissen, E.D., Kent, D.R., Nissen, S.E. (1979).Role of oral contraceptive agents in the pathogenesis of liver tumors. J Toxicol Environ Health,5(2-3), 231-54.

[92] Ruiz Lopez, D., Sanchez Salvador, J., Fernandez Martin, C., Anton Diaz, E. (2005). Hepatic adenoma related to oral contraceptives use. Aten. Primaria,35(2), 109-10.

[93] Ferrara, B.E., Rutland, E.D. (1988). Liver tumor in long-term user of oral contraceptives. Postgrad. Med, 84(6), 107-9.

[94] Teeuwen, P.H., Ruers, T.J.,Wobbes, T. (2007). Hepatocellular adenoma, a tumour particularly seen in mostly young women. Ned. Tijdschr. Geneeeskd. 151(24),1321-4.

[95] Barthelmes L., Tait I.S. (2005). Liver cell adenoma and liver cell adenomatosis. HPB (Oxford), 7(3), 186-96.

[96] Sherlock, S. (1979). Hepatic adenomas and oral contraceptives. J.Toxicol. Environ.Health, 5(3), 231-54.

[97] Aseni, P., Sansalone C.V., Sammartino C., Benedetto F.D., Carrfiello G., Giacomoni A., Osio C., Vertemati M., Forti D. (2001). Rapid disappearance of hepatic adenoma after contraceptive withdrawal. J. Clin. Gastroenterol, 33(3), 234-6.

[98] Steinbrecher,V.P., Lisbona, R., Huang, S.N.,Mishkin, S. (1981). Complete regression of hepatocellular adenoma after withdrawal of oral contraceptives. Dig. Dis. Sci, 26(11), 1045-50.

[99] Svrcek, M., Jeannot, E., Arrive, L., Poupon, R., Fromont, G., Flejou, J.F., Zucman-Rossi, J., Bouchard, P., Wendum, D. (2007). Regressive liver adenomatosis following androgenic progestin therapy withdrawal: a case report with a 10-year follow-up and a molecular analysis. Uur.J. Endocrinol, 156(6), 617-21.

[100] Gordon, S.C., Reddy, K.R., Livingstone, A.S., Jeffers, L.J. (1986). Schiff ERResolution of a contraceptive- steroid-induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. Ann. Intern.Med, 105(4), 547-9

[101] Ito, M., Sasaki, M.,Wen, C.Y., Nakashima, M.,Ueki, T., Ishibashi, H.,Yano, M., Kage, M. (2003). Liver cell adenoma with malignant transformation: a case report. World J.Gastroenterol,9 (10), 2379-81.

[102] Gyorffy, E.J., Bredfeldt, J.E., Black, W.C. (1989). Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use. Ann.Intern.Med, 110(6), 489-90

[103] Herman, P., Machado, M.A.,Volpe, P., Pugliese, V.,Vianna, M.R., Bacchella, T., Machado, M.C., Pinotti, H.W. (1994). Transformation of hepatic adenoma into hepatocellular carcinoma in patients with prolonged use of oral contraceptives. Rev.Hosp.Clin.Fac.Med.Sao Paulo, 49(1), 30-3.

[104] Korula, J.,Yellin, A.,Kanel, G.,Campofiori, G., Nichols, P. (1991). Hepatocellular carcinoma coexisting with hepatic adenoma.Incidental discovery after long-term oral contraceptive use.West J.Med, 155(4), 416-8.

[105] Perret, A.G., Mosnier, J.F., Porcheron, J.,Cuilleron, M., Berthoux, P., Boucheron, S., Audigier, J.C. (1996). Role of oral contraceptives in the growth of a multilobular adenoma associated with a hepatocellular carcinoma in a young woman. J.Hepatol, 25(6), 976-9.

[106] Tao, L.C. (1991). Oral contraceptives-associated liver cell adenoma and hepatocellular carcinoma. Cytomorphology and mechanism of malignant transformation. Cancer, 68(2), 341-7.

[107] Shortell, C.K., Schwartz, S.I. (1991).Hepatic adenoma and focal nodular hyperplasia. Surg. Gynecol. Obstet, 173(5), 426-31.

[108] Tajada, M., Nerin, J., Ruiz, M.M., Sanchez-Dehesa, M., Fabre, E. (2001).Liver adenoma and focal nodular hyperplasia associated with oral contraceptives. Eur. J. Contracept. Reprod. Health Care, 6(4),227-30.

[109] Scalori, A., Tafani, A.,Gallus, S., La Vecchia, C., Colombo, M. (2002). Oral contraceptives and the risk of focal nodular hyperplasia of the liver:a case - control study. Am.J.Obstet. Gynecol, 186(2), 195-7.

[110] Giannitrapani, L., Soresi, M., La Spada, E., Cervello, M., D'Alessandro, N., Montalto, G. (2006). Sex hormones and risk of liver tumor. Ann N Y Acad Sci,1089,228-36

[111] Torbenson, M., Lee, J.H., Choti, M., Gage, W., Abraham, S.C., Montgomery, E., Boitnott, J., Wu, T.T. (2002). Hepatic adenomas: analysis of sex steroid receptor status and the Wnt signaling pathway. Mod Pathol, 15(3),189-96

[112] Cohen, C., Lawson, D., DeRose, P.B. (1998). Sex and androgenic steroid receptor expression in hepatic adenomas.Hum.Pathol, 29(12), 1428-32. Toso, C., Rubbia - Brandt, L., Negro, F., Morel, P., Mentha, G. (2003). Hepatocellular adenoma and polycystic ovary syndrome.Liver Int,23(1), 35-7.

[113] La Vecchia, C., Altieri, A., Franceschi, S., Tavani, A. (2001). Oral contraceptives and cancer: an update. Drug Saf, 24(10), 741-54.

[114] Shilling, M.K., Zimmermann, A., Radaelli, C., Seiler, C.A., Buchler, M.W.(2000). Liver nodules resembling focal nodular hyperplasia after hepatic venous thrombosis.J.Hepatol, 33(4), 673-6.

[115] Tong, H.K., Fai, G.L., Ann, L.T., Hock, O.B. (1981). Budd-Chiari syndrome and hepatic adenomas associated with oral contraceptives. A case report. Singapore Med.J, 22(3), 168-72.

[116] Buhler, H., Pirovino, M., Akoblantz, A., Altofer, J., Weitzel, M., Maranta, E., Schmid, M. (1982). Regression of liver cell adenoma. A follow-up study of three consecutive patients after discontinuation of oral contraceptive use.Gastroenterology, 82(4), 775-82.

[117] Overdiek, A.,Winner, U., Mayatepek, E., Rosenbaum, T. (2008). Schwann cells from human neurofibromas show increased proliferation rates under the influence of progesterone. Pediatric.Res, Mar 19 (Epub ahead of print).

[118] McLaughlin, M.E., Jacks, T. (2003). Progesterone receptor expression in neurofibromas.Cancer Res, 63(4), 752-5.

[119] Fishbein, L., Zhang, X., Fisher, L.B., Li, H., Campbell-Thompson, M.,Yachnis, A., Rubenstein, A., Muir, D.,Wallace, M.R. (2007). In vitro studies of hormones in neurofibromtosis 1 and Schwann cells. Mol.Carcinog, 46(7), 512-23.

[120] Lammert, M., Mautner, V.F., Kluwe, L. (2005). Do hormonal contraceptives stimulate growth of neurofibromas?A survey on 59 NF1 patients. BMC Cancer, 5, 16.

[121] Skinner, H.G., Michaud, D.S., Colditz, G.A.,Giovannucci, E.L., Stampfer, M.J.,Willett, W.C., Fuchs, C.S. (2003). Parity, reproductive factors, and the risk of pancreatic cancer in women.Cancer Epidemiol. Biomarkers Prev, 12(5),433-8.

[122] NavarroSilvera, S.A., Miller, A.B., Rohan, T.E. (2005). Hormonal and reproductive factors and pancreatic cancer risk: a prospective cohort study. Pancreas, 30(4), 369-74

[123] Kreiger, N., Lacroix, J., Sloan, M. (2001). Hormonal factors and pancreatic cancer in women. Ann. Epidemiol, 11(8), 563-7.

[124] Lo, A.C., Soliman, A.S., El-Ghawalby, N., Abdel-Wahab, M., Fathy, O., Khaled, H.M., Omar, S., Hamilton, S.R., Greenson, J.K., Abbruzzese, J.L. (2007). Lifestyle, occupational, and reproductive factors inrelation to pancreatic cancer risk.Pancreas,Aug, 35(2), 120-9.

[125] Prizment, A.E., Anderson, K.E., Hong, C.P., Folsom, A.R. (2007). Pancreatic cancer incidence in relation to female reproductive factors: Iowa Women's Health Study. JOP,Jan 9, 8(1), 16-27.

[126] Teras, L.R., Patel, A.V., Rodriguez, C., Thun, M.J., Calle, E.E. (2005). Parity, other reproductive factors, and risk of pancreatic cancer mortality in a large cohort of U.S. women (United States).Cancer Causes Control, 16(9), 1035-40.

[127] Abe, M., Yamashita, J., Ogawa, M. (2000). Medroxyprogesterone acetate inhibits human pancreatic carcinoma cell growth by inducing apoptosis in association with Bcl-2 phosphorylation. Cancer, 88(9),2000-9.

[128] McGrath, M., Michaud, D.S., De Vivo, I. (2006). Hormonal and reproductive factors and the risk of bladder cancer in women. Am. J. Epidemiol,163(3), 236-44.

[129] Cantwell, M.M., Lacey, J.V.Jr., Schairer, C., Schatzkin, A., Michaud, D.S. (2006). Reproductive factors, exogenous hormone use and bladder cancer risk in a prospective study. Int.J.Cancer,119,2398-401

[130] Rossing, M.A.,Voigt, L.F., Wicklund, K.G.,Williams, M., Daling, J.R. (1998). Use of exogenous hormones hormones and risk of papillary thyroid cancer (Washington, United States). Cancer Causes Control, 9(3), 341-9.

[131] Custer, B., Longtreth, W.T. Jr., Phillips, L.E., Koepsell, T.D.,Van Belle, G. (2006). Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. BMC Cancer, 6,152.